The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 8.80 — safe zoneOK
- Earnings-manipulation signal · Beneish M -0.18 — flag raised, worth a closer lookWatch
- Earnings quality 53/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as ADMA BIOLOGICS, INC. reports it. History and quarterly detail are in the app.
- ADMA Bio Manufacturing$493.1M
- Plasma Collection Centers$17.0M
Leadership changes
From ADMA BIOLOGICS, INC.'s own filings, the day they're filed.
- Eduardo Rene Salas · director · appointmenteff. 2024-12-30
- Young T. Kwon · Chairman · appointmenteff. 2024-11-19
- Bryant E. Fong · Directors · departureeff. 2024-11-19
Latest filings
- 8-K · Company announcement2026-06-02
- 8-K · Company announcement2026-05-06
- 10-Q · Quarterly report2026-05-06
- 8-K · Company announcement2026-05-04
- DEF 14A · Annual proxy (pay & governance)2026-04-15
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about ADMA BIOLOGICS, INC., every answer cited🔒
- The Intelligence Brief — added when ADMA BIOLOGICS, INC.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.